Literature DB >> 10977770

Management of irregular astigmatism.

M Goggin1, N Alpins, L M Schmid.   

Abstract

Using a liberal definition of corneal irregularity, modern videokeratoscopy may define approximately 40% of normal corneas with a toric refractive error as possessing primary irregular astigmatism. The causes of secondary forms of irregular astigmatism include corneal surgery, trauma, dystrophies, and infections. Internal refractive surface and media irregularity or noncorneal astigmatism (ocular residual astigmatism) contribute to irregular astigmatism of the entire refractive path of which crystaline lenticular astigmatism is usually the principal contributing component. Treatment options have increased in recent years, particularly, though not exclusively, through the advent of tailored corneal excimer laser ablations. However, discussion continues concerning the systematic approach necessary to enable treatment to achieve an optimal optical surface for the eye. Discussion also continues as to what constitutes the optimal corneal shape. Some refractive procedures may increase higher order aberrations in the attempt to neutralize refractive astigmatism. The way to further refinement of the commonly performed refractive techniques will ultimately lie in the integrated inclusion of a trio of technologies: topographic analysis of the corneal surface, wavefront analysis of ocular refractive aberrations, and vector planning to enable the appropriate balance in emphasis between these two diagnostic modalities. For the uncommon, irregularly roughened corneas, the ablatable polymer techniques show some promise.

Entities:  

Mesh:

Year:  2000        PMID: 10977770     DOI: 10.1097/00055735-200008000-00007

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  7 in total

1.  Contact lenses and special back surface design after penetrating keratoplasty to improve contact lens fit and visual outcome.

Authors:  C Gruenauer-Kloevekorn; U Kloevekorn-Fischer; G I W Duncker
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

2.  Validity of autorefractor based screening method for irregular astigmatism compared to the corneal topography- a cross sectional study.

Authors:  Alicia Galindo-Ferreiro; Julita De Miguel-Gutierrez; Manuel González-Sagrado; Alberto Galvez-Ruiz; Rajiv Khandekar; Silvana Schellini; Julio Galindo-Alonso
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

3.  Intraocular lens power calculation in patients with irregular astigmatism.

Authors:  Asaf Achiron; Omar Elhaddad; Duncan Leadbetter; Eliya Levinger; Oleksiy Voytsekhivskyy; Katy Smith; Venkata Avadhanam; Kieren Darcy; Derek Tole
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-01       Impact factor: 3.117

4.  Long-term outcomes of wedge resection at the limbus for high irregular corneal astigmatism after repaired corneal laceration.

Authors:  Jun Du; Guang-Ying Zheng; Cheng-Lin Wen; Xiao-Fang Zhang; Yu Zhu
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

5.  Correction of Myopic Astigmatism with Topography-Guided Laser In Situ Keratomileusis (TOPOLINK).

Authors:  Pei-Lun Wu; Chia-Yi Lee; Han-Chih Cheng; Hung-Yu Lin; Li-Ju Lai; Wei-Chi Wu; Hung-Chi Chen
Journal:  Healthcare (Basel)       Date:  2020-11-11

6.  Aberrometric, Keratometric, and Visual Outcomes After Trans-Epithelial Topography-Guided Phototherapeutic Keratectomy for the Treatment of Irregular Corneas.

Authors:  Antonio Cano-Ortiz; Pablo Morales; Álvaro Sánchez-Ventosa; Isabel Leiva-Gea; Alberto Membrillo; Vasyl Druchkiv; Timoteo González-Cruces; José-María Sánchez-González; Jaime Beltrán; Alberto Villarrubia
Journal:  Clin Ophthalmol       Date:  2021-09-07

7.  Outcomes of a Management Strategy in Eyes with Corneal Irregularity and Cataract.

Authors:  Mathew Kurian Kummelil; Rohit Shetty; Luci Kaweri; Shama Shaligram; Mukesh Paryani
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.